ZyVersa grants 100,000-share option inducement to new CMO Dr. Pablo Guzman at $2.11

ZyVersa Therapeutics, Inc.

Nonqualified stock option to purchase 100,000 shares at $2.11/share, the Jan 25, 2023 closing price.
Option has 10-year term, vests in three equal annual installments starting Jan 26, 2024, subject to continued service.
Grant approved by Compensation Committee as inducement material to Dr. Guzman's employment as CMO and SVP of Medical Affairs.
Inducement award was granted outside ZyVersa's 2022 Equity Incentive Plan under Nasdaq Rule 5635(c)(4).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.